In breast cancer cells, UBE2C silencing inhibits ERK and AKT phosphorylation and increases the levels of phosphorylated PTEN, which acts as a negative regulator of the PI3K/AKT pathway [58]. This evidence concerns the gene AKT1 and breast carcinoma.